Beneath these two data points, a third pattern is assembling quietly. The ibogaine cardiac review was not produced by opponents of treatment — it was produced by researchers preparing the ground for FDA-acceptable monitoring protocols, likely in dialogue with the Stanford ibogaine veteran study's safety infrastructure. The DEA's 8-factor analysis, should rescheduling ever be formally petitioned, will cite this same literature as evidence of unresolved risk. The same data that enables responsible clinical programs also furnishes the procedural vocabulary of delay. This dual-use quality of safety science — simultaneously enabling and obstructing — is the defining structural tension of the psychedelic field in 2026.
The deeper current running beneath all of this is a field in the process of being sorted. What is sorting it is not politics, not ideology, not even efficacy data — it is mechanistic specificity. Investors have learned that positive headlines do not predict approval timelines. Regulators have learned that veteran advocacy does not override cardiac liability. Journalists have learned, or are about to relearn, that extinction effects and relapse prevention are not synonymous. The highest trajectory available from here is not one where these distinctions collapse back into optimism — it is one where they sharpen into protocols precise enough to satisfy the FDA's biomarker requirements for COMPASS's NDA, specific enough to give ibogaine's cardiac monitoring framework genuine clinical teeth, and honest enough to convert the psilocybin cocaine finding into a real design question rather than a media controversy. The field that earns approval will be the field that earned precision first.
The human beings most directly inside today's signal are the veterans — the ones who traveled to clinics in Mexico or Costa Rica, who have seen ibogaine interrupt decades of treatment-resistant PTSD in ways that nothing sanctioned came close to touching, who are now watching the same cardiac safety data that saved their lives become the procedural grounds for indefinite scheduling delay. They are not naïve about risk. They consented to it. What they are waiting for is not a guarantee of safety but an acknowledgment that the calculus of risk looks different when the alternative is a loaded firearm or a twenty-year opioid dependency. The highest positive outcome genuinely available from here is a formal FDA cardiac monitoring framework for ibogaine IND submissions — not rescheduling, not immediate access, but the creation of a regulated pathway where that consent can happen inside a system rather than outside it. That is the thread. It is forming. The Stanford data will be pivotal, and the scoping review published today, read correctly, is part of what makes the Stanford protocol legible to regulators who have never seen this molecule before.
The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first.
Every thread you follow today was laid by a hand that knew you were coming.
71%
Ibogaine stays illegal through 2029 because of heart risks, despite veteran pressure
Ibogaine—a West African plant used by some to treat addiction—will remain a Schedule I controlled substance (meaning illegal with no accepted medical use) through the end of 2029. The DEA (the US drug enforcement agency) will cite documented cardiac (heart) dangers as their reason to reject rescheduling, even though veterans and activists push hard for legal access and companies are already running FDA (US drug regulator) approved clinical trials.
→ A single serious safety concern (heart problems) gives regulators enough reason to say no for years, even if the drug might help people.
Resolves: 2029-12-31 · USA
REGULATION
the precise call ▾
Ibogaine will remain Schedule I through December 31, 2029, with DEA's 8-factor analysis citing cardiac liability as sufficient procedural basis to deny rescheduling despite active IND filings and veteran advocacy pressure. DEA scheduling timelines are structurally slow; no substance with documented cardiac risk has been rescheduled against active safety objections. The cardiac scoping review published in May 2026 gives DEA citable evidence. Veteran sympathy has real political salience but has not historically overridd
67%
Compass Pathways stock won't bounce back above $12.50 by August 2026
Compass Pathways (CMPS)—a company developing psilocybin therapy—will not see its stock price climb back above $12.50 by mid-August 2026. This matters because it shows that publishing research papers and positive clinical results alone don't move stock prices anymore. Only big announcements (FDA approval meetings, or one company buying another) actually make institutional investors (the big money players) move.
→ Publishing good research doesn't make a psychedelic company's stock price go up—only regulatory approval or mergers do.
Resolves: 2026-08-19 · USA
MARKET
the precise call ▾
CMPS (Compass Pathways) will not recover above $12.50 by August 19, 2026, confirming that publication volume is not an investable catalyst and only binary FDA events or M&A signals move institutional psychedelic capital. Recent price action shows multiple landmark publications failing to produce sustained price appreciation — this establishes a revealed preference by institutional capital. The $12.50 threshold requires significant upside from current levels on publication alone, which the market has now repeatedly n
62%
Psilocybin-cocaine study gets mangled in 72 hours, then correction itself becomes a credibility scandal
When researchers publish a surprising finding about psilocybin and cocaine addiction, mainstream news outlets will oversimplify or misrepresent the actual results within three days. When scientists try to publicly correct these errors, journalists will frame the whole situation as evidence that psychedelic science hypes itself up—turning the correction effort into another credibility problem instead of fixing the original one.
→ Good science won't protect you from bad headlines, and trying to correct bad headlines can actually hurt your credibility more.
Resolves: 2026-05-22 · Global
CULTURE
the precise call ▾
The psilocybin cocaine RCT will be significantly misrepresented in at least three major mainstream media outlets within 72 hours of publication, and a researcher-led public correction effort will itself generate coverage framing psychedelic science as prone to hype cycles. The extinction-without-relapse-prevention finding is technically nuanced and counterintuitive enough that deadline-pressured journalists will omit critical caveats. Multi-agent consensus (journalist, neuropharmacologist, fda_reviewer) supports this. The correction campaign becoming a credibility sto